Form 4: Eton Pharmaceuticals CEO and 10% Owner Sells 210,000 Shares in Early June

Sean Brynjelsen, President and CEO and a 10% owner of Eton Pharmaceuticals, Inc., reported the sale of 210,000 shares of common stock over three trading days in early June 2025.

Summary

• Sean Brynjelsen, who serves as Director, 10% Owner, and President & CEO of Eton Pharmaceuticals, Inc. (ETON), reported multiple sales of common stock.
• On June 3, 2025, Mr. Brynjelsen sold a total of 69,999 shares of common stock in three separate transactions: 60,945 shares at a weighted average price of $17.38, 8,655 shares at a weighted average price of $18.38, and 400 shares at $19.02.
• On June 4, 2025, an additional 70,000 shares of common stock were sold at a weighted average price of $17.00.
• On June 5, 2025, a further 70,000 shares of common stock were sold at a weighted average price of $16.81.
• In total, 210,000 shares of Eton Pharmaceuticals common stock were disposed of by Mr. Brynjelsen across these three days.
• Following these transactions, Sean Brynjelsen beneficially owns 2,873,513 shares of Eton Pharmaceuticals common stock.

Sentiment

Score: 3

Explanation: The significant volume of insider selling by the President & CEO and a 10% owner typically signals a lack of confidence in the company's future performance, which is a negative indicator for investors.

Negatives

• Significant insider selling by the President & CEO and a 10% owner can be interpreted as a negative signal regarding management's confidence in the company's future prospects.
• The sales occurred over consecutive trading days, indicating a concentrated effort to reduce holdings.

Management Comments

• The reporting person has authorized and designated James R. Gruber to file this Form 4 on their behalf for an indefinite duration.

Industry Context

This Form 4 filing details an individual insider transaction and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders may perceive the significant insider selling by the CEO and a 10% owner as a negative signal, potentially leading to decreased investor confidence and downward pressure on the stock price.

Key Dates

Recommendation

Keywords

Eton Pharmaceuticals, ETON, Insider Selling, Form 4, Stock Sale, Sean Brynjelsen, CEO, 10% Owner, Equity Transaction